[{"Assets_0_Q3_USD":1446700000.0,"EarningsPerShareDiluted_3_Q3_USD":-1.94,"EarningsPerShareDiluted_1_Q3_USD":-1.55,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":74200000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":74500000.0,"EarningsPerShareBasic_3_Q3_USD":-1.94,"EarningsPerShareBasic_1_Q3_USD":-1.55,"StockholdersEquityConverted_0_Q3_USD":967200000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":74200000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":74500000.0,"StockholdersEquity_0_Q3_USD":967200000.0,"NetIncomeLossConverted_3_Q3_USD":-144100000.0,"NetIncomeLossConverted_1_Q3_USD":-115200000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_3_Q3_USD":30700000.0,"CommonStockSharesOutstanding_0_Q3_shares":74500000.0,"CommonStockSharesConverted_0_Q3_shares":74500000.0,"RevenuesConverted_1_Q3_USD":164000000.0,"RevenuesConverted_3_Q3_USD":545400000.0,"Ticker":"MYGN","CIK":"899923","name":"MYRIAD GENETICS INC","OfficialName":"Myriad Genetics Inc. Common Stock","form":"10-Q","period":"20200331","fy":"2020.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1850258412.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20200506"}]